A Genetic Mystery, a Lethal Cancer, and the Improbable Invention of a Life-Saving Treatment
Author: Jessica Wapner
Publisher: The Experiment
The discovery of a cancer-causing genetic mutation leads to a lifesaving miracle drug in this “absorbing, complex medical detective story” (Kirkus Reviews). Philadelphia, 1959. A scientist scrutinizing a single human cell detects a missing piece of DNA. That scientist, David Hungerford, has just stumbled on the starting point of modern cancer research?the Philadelphia chromosome. It would take doctors and researchers around the world more than three decades to unravel the implications of this landmark discovery. In 1990, the Philadelphia chromosome was recognized as the sole cause of a deadly blood cancer, chronic myeloid leukemia, or CML. Cancer research would never be the same. With extensive research and numerous personal interviews, science journalist Jessica Wapner reconstructs the decades-long journey from Hungerford’s discovery to a breakthrough, lifesaving treatment. A chronicle of scientific rigor and determination, The Philadelphia Chromosome celebrates a rare triumph in the battle against cancer while offering a blueprint for future research. One of The Wall Street Journal’s 10 Best Nonfiction Books of 2013
The Second Edition Of This Authoritative Text Details Major Advances And Developments In The Field, Such As The Identification Of Many New Tumor Suppressor Genes And The Striking Progress In Understanding Signal Transduction Pathways Leading To Cell Proliferation. Oncogenes, Second Edition, Addresses The Needs Of Advanced Undergraduates, Graduate Students, Medical Students, Physicians, And Scientists By Examining The Current State Of Oncogene Study And Where Future Research May Lead.
This concise guidebook consolidates the main concepts of the cancer gene theory, and provides a framework for understanding the genetic basis of cancer. Focused on the most highly representative genes that underlie the most common cancers, the book is aimed at advanced undergraduates who have completed introductory courses in genetics, biology and biochemistry, medical students, and house medical house staff preparing for board examinations. Primary attention is devoted to the origins of cancer genes and the application of evolutionary theory to explain why the cell clones that harbor cancer genes tend to expand.
Leukemia continues to offer the scientist a unique opportunity to gain new knowledge about the malignant transformation. As a result, this multi-authored volume, devoted to advances which have occurred over the last seven years, provides the reader with an important new understanding of leukemia, but perhaps even more important, predicts analogous, new developments in the other malignant diagnoses. In this respect, this volume represents the cutting edge of cancer research. This text is unique in that it includes in a single volume the leading contributors to their respective fields covering what the editors feel are the major advances in our knowledge of the biology and therapy of leukemia over the last seven years.
This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of leukemia treatment. Leukemia treatment has undergone major change over the course of the past few years and Leukemia addresses current best practices in the light of the most recent evidence. With contributions from experts across the US and Canada, Leukemia details the current management of different types of leukemia and reviews new therapies in development for various forms of acute leukemia, chronic leukemia, myelodysplastic syndrome, and myeloproliferative disorders. Coverage includes new developments in hematopoitic cell transplantation, leukemia pathology and management, immunotherapy and targeted therapies. It is a valuable tool for clinicians, nurses, researchers, medical students, residents, and fellows. Emerging Cancer Therapeutics Series Titles Features: Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics Issues edited by an authority in specific subject area Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience Emphasizes multidisciplinary approaches to research and practice
This book is directed primarily to advanced graduate and medical students, postdoctoral trainees, and established investigators having basic research interests in neoplasia. Its content is based in part on the lecture outlines and selected histopathology laboratory components of an advanced course entitled The Pathobiology of Experimental Animal and Human Neoplasia, developed by me for the Experimental Pathology Curriculum of the Department of Pathology at the Medical College of Virginia. In this regard, an effort has been made to integrate pathology with carcinogenesis, genetics, biochemistry, and cellular and molecular biology in order to present a comprehensive and current view of the neoplastic process. For focus, emphasis is mainly being placed on the neoplastic cells themselves, and not on associated host-mediated responses. It ishoped that this book will accomplish its purpose of providing students and researchers who already possess strong but diverse basic science backgrounds with unifying concepts in tumor pathobiology, so as to stimulate new research aimed at furthering our understanding of neoplastic disease. I wish to express my appreciation and heartfelt thanks to the authors, whose individual ranges of expertise and research experience clearly bring to their respective chapters unique perspectives that easily transcend any redundancy that may be present. In addition, I am grateful to Drs. George Vennart, Saul Kay, and Fred Meier, and to Ms. Connie Wilkerson of the Department of Pathology at MCV, for their helpful comments and their review of some of the material.